Evidence map›Paper›PMID 39640230›Full record

ArticleJACC. Advances2024

Association of Lipoprotein(a) With Major Adverse Cardiovascular Events Across hs-CRP: A Systematic Review and Meta-Analysis.

Pamela L Alebna, Chin Yip Han, Mathew Ambrosio, Gwyneth Kong, John W Cyrus, Kayla Harley, Le Kang, Aeron M Small, Parag Chevli, Harpreet Bhatia and 7 more

Abstract read
In one paragraph

Article in JACC. Advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Pamela L AlebnaPauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA.
Chin Yip HanDepartment of Cardiology, National University Heart Centre, National University Health System, Singapore, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Mathew AmbrosioDepartment of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
Gwyneth KongDepartment of Cardiology, National University Heart Centre, National University Health System, Singapore, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
John W CyrusHealth Sciences Library, Virginia Commonwealth University, Richmond, Virginia, USA.
Kayla HarleyDepartment of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
Le KangDepartment of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
Aeron M SmallDivision of Cardiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Parag ChevliDivision of Cardiology, Wake Forest Baptist Health, Winston-Salem, North Carolina, USA.
Harpreet BhatiaDivision of Cardiology, University of California San Diego, California, USA.
Nicholas ChewDepartment of Cardiology, National University Heart Centre, National University Health System, Singapore, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Fadi N SalloumDepartment of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
Dave L DixonDepartment of Pharmacotherapy & Outcomes Science, VCU School of Pharmacy, Richmond, Virginia, USA.
Antonio AbbateDivision of Cardiology, Berne Cardiovascular Research Center, University of Virginia, Charlottesville, Virginia, USA.
Pradeep NatarajanDivision of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Michael D ShapiroDivision of Cardiology, Wake Forest Baptist Health, Winston-Salem, North Carolina, USA.
Anurag MehtaPauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, USA.

Funding

Managing Cardiac Toxicities of Cancer TherapyR35HL155651 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Fadi N Salloum · 2021 to 2026
$4.6M
Multi-Disciplinary Training Program in Translational Cardiovascular ResearchT32HL149645 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Lauren Ashley Cowart, William Gregory Hundley · 2020 to 2026
$2.2M
Aspirin for Primary Prevention of Cardiovascular Disease in Patients with Elevated Lipoprotein(a)K08HL166962 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Harpreet Singh Bhatia · 2023 to 2026
$676k
NHLBI NIH HHS K08 HL166962NHLBI NIH HHS R35 HL155651NHLBI NIH HHS T32 HL149645
6 · The paper itself

Abstract

Background: Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease. The relationship between Lp(a) and major adverse cardiovascular events (MACE) in the context of high-sensitivity C-reactive protein (hs-CRP) levels remains controversial due to conflicting results from previous studies. Objectives: This systematic review and meta-analysis aimed to clarify the association between Lp(a) and risk of MACE across different hs-CRP levels in both primary and secondary prevention settings. Methods: We performed a systematic review by searching MEDLINE (PubMed), Embase (Ovid), Cochrane CENTRAL (Wiley), and Web of Science (Clarivate) from their inception to February 2024. Eligible studies reported the association of Lp(a) with MACE stratified by hs-CRP level. Data extraction and quality assessment were systematically conducted. Meta-analyses used random-effects models to compute pooled HRs for individuals with low (<2 mg/L) and high (≥2 mg/L) hs-CRP levels. Subgroup analyses were performed in primary and secondary prevention populations. Results: Nine publications encompassing 11 studies that involved 562,301 participants met the inclusion criteria. The mean proportion of females was 39.9% and the weighted mean age for the entire cohort was 61.2 years. Elevated Lp(a) was significantly associated with MACE risk in both low and high hs-CRP groups, with pooled HR of 1.26 (95% CI: 1.11-1.42) and 1.33 (95% CI: 1.20-1.47), respectively. In the primary prevention group, the pooled HR for low and high hs-CRP groups was 1.33 (95% CI: 1.06-1.66) and 1.43 (95% CI: 1.13-1.82), respectively (subgroup difference, Conclusion: Elevated Lp(a) is associated with an increased risk of MACE independent of hs-CRP levels in both primary and secondary prevention populations.

Indexed as

cardiovascular outcomesinflammationLp(a)

Identifiers

PMID39640230
PMCPMC11617504

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.